Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT03859921
Recruiting Phase 3

Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET

NCT03859921 · tracked via the Priya Life Science China tracker
Sponsor
The University of Hong Kong
Phase
Phase 3
Started
2021-07-01
Last updated
2025-06-12

Condition(s) studied

Subfertility

Investigational drug(s) / intervention(s)

Dydrogesterone →Placebo

Dydrogesterone: Progesterone

Placebo: Placebo with appearance similar to Dydrogesterone

Study summary

This randomised double-blinded controlled trial aims to compare the live birth rate in natural FET cycles with and without oral dydrogesterone as luteal phase support. The hypothesis is that the use of oral dydrogesterone will increase the live birth rate of natural cycle FET.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
42 Years
Healthy volunteers
No
Inclusion Criteria: * Age of women \<43 years at the time of stimulated IVF * Replacing early cleavage embryos or blastocysts after thawing Exclusion Criteria: * Requiring hormonal replacement cycles * Use of donor oocytes or embryos * Undergoing preimplantation genetic testing * Presence of hydrosalpinx not corrected surgically prior to FET * Refusal to join the study

Primary outcome measure(s)

  • live birth rate — 10 months after recruitment
    the number of live birth beyond 22 weeks gestation per transfer cycle

Trial sites (1)

FacilityCityRegionStatus
Department of Obstetrics and Gynaecology Hong Kong Hong Kong Recruiting

More The University of Hong Kong trials in China

The "Quit-for-Kids" Project: to Increase Abstinence and Protect Children From Tobacco Smoke Exposure Recruiting
Testing the Performance of Smartphones and Their Accessories in Detecting Irregularly Irregular Heart Rhythm Enrolling by invitation
Role of Exercise in PRISm and Subsequent Development of COPD Recruiting
Pleurodesis in Small-bore Chest Tube Starting soon
GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET Recruiting

Other trials for the same condition

GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03859921 on ClinicalTrials.gov ↗ ← All trials in China